Jianming Wang, Qiguang Wang^*, Xiaotang Sheng, Jingsong Geng, Jiawang Xiao, Xianyang Zhu^*

Congenital Heart Disease, Vol.18, No.2, pp. 183-195, 2023, DOI:10.32604/chd.2022.021855 - 15 March 2023

Abstract Objective: This study was designed to determine the long-term safety and efficacy of using the Amplatzer Duct Occluder II (ADO II) for the closure of various ventricular septal defects (VSDs). Methods: From January 2011 to December 2019, selected VSD patients were treated through transcatheter intervention using ADO II occluders. The closure results and complications from 188 patients, involving 167 perimembranous ventricular septal defects (pmVSDs), 9 intracristal VSDs, 11 post surgery residual shunts and 1 post closure residual shunt with the mean outlet diameter3.1 ± 0.8 mm under angiography, were enrolled in this study. Results: The success rate… More >

Hongxiao Sun, Gang Luo, Zhanhui Du, Zhixian Ji, Silin Pan^*

Congenital Heart Disease, Vol.16, No.2, pp. 151-157, 2021, DOI:10.32604/CHD.2021.014770 - 26 January 2021

Abstract Objective: To evaluate the efficacy of Amplatzer duct occluder II (ADO II) in the treatment of perimembranous ventricular septal defect (pmVSD) in children. Methods: Between June 2017 and June 2020, 13 patients with pmVSD had attempted transcatheter closure using ADO II, seven of patients were used antegrade approach and six of them were used retrograde approach. Results: There were 8 males and 5 females, age from 1 to 7 years, weight from 10.5 to 31.0 kg, and VSD size from 2.0 to 4.0 mm. Procedure was successful in all cases with the outer diameter of the occluders More >

Anoosh Esmaeili, Kachina Behnke‐Hall, Roland Schrewe, Dietmar Schranz

Congenital Heart Disease, Vol.14, No.3, pp. 389-395, 2019, DOI:10.1111/chd.12731

Abstract Aim: The purpose of this study is to describe the special aspects of perimembranous ventricular septal defects (pmVSD) closure by utilizing Amplatzer Duct Occluder II (ADO II) devices with a rational request for bigger ADO‐II sizes, based on our experi‐ ence in transcatheter device closure of pmVSD.
Methods and Results: At our institution, placement of an ADO II device was used in 15 patients with pmVSD; the patients’ age ranged between 6 months and 20 years. The indications for closure were CHF (n = 4), hemodynamically significant shunt (n = 7), tricuspid regurgitation (n = 3), and… More >